Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
depigmented modified mite allergen extract (Dermatophagoides pteronyssinus + Lepidoglyphus destructor)
- Development stage
- Unknown
- Lead developer
- Leti Pharma
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Depigmented modified mite allergen extract (Dermatophagoides pteronyssinus + Lepidoglyphus destructor), also identified as DP/MG/14-2, is a subcutaneous allergen immunotherapy (SCIT) product developed by Laboratorios LETI. It is a biologic allergoid consisting of glutaraldehyde-polymerized, depigmented allergen extracts derived from two house dust mite species: the pyroglyphid *Dermatophagoides pteronyssinus* and the glycyphagid *Lepidoglyphus destructor*. The depigmentation and polymerization processes are designed to reduce allergenicity (IgE binding) while maintaining immunogenicity, thereby improving safety during the build-up phase. The drug targets the IgE-mediated allergic immune response to house dust mite allergens and is intended to induce long-term allergen tolerance. It was evaluated in a multicenter, open-label Phase IIb clinical trial (NCT02340130) for the treatment of allergic rhinitis, allergic rhinoconjunctivitis, and controlled allergic asthma in adults sensitized to these mite species.
- Other names
- DP/MG/14-2
02
Targets
BCR (Immunoglobulin G B Cell Receptor)House dust mite allergen-specific T-cell receptor (HDM-specific TCR)
Beyond the preview
Go deeper on depigmented modified mite allergen extract (Dermatophagoides pteronyssinus + Lepidoglyphus destructor).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on depigmented modified mite allergen extract (Dermatophagoides pteronyssinus + Lepidoglyphus destructor).